[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"laryngeal-dystonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:laryngeal-dystonia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,43,70,97,118,140,155,172,189,212],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100596111","phase-1-extended-release-sodium-oxybate-lumryz-in-spasmodic-dysphonia-and-voice-tremor-100596111",false,"NCT07041203","Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor","Central Mechanisms and Treatment Response of Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and lifestyle considerations (see Lifestyle Considerations below) and availability for the duration of the study\n3. Males and females\n4. Age 21-80 years\n5. Documented diagnosis of alcohol-responsive laryngeal dystonia\n6. Documented positive response to immediate-release sodium oxybate (Xyrem) in prior studies\n7. Willingness to adhere to the study intervention regimen\n\nExclusion Criteria:\n\n1. The incapability of giving informed consent\n2. Pregnancy or breastfeeding until a time when they are no longer pregnant or breastfeeding\n3. Grade 2 or higher hepatic or renal dysfunction according to the NCI criteria\n4. Moderate to severe congestive heart failure\n5. Cognitive impairment (MoCA \\\u003C 26)\n6. Past or present suicidal ideations (according to C-SSRS)\n7. Alcoholism or high risk for alcohol use disorder according to the NIAAA definition and DSM-5 criteria\n8. Asymptomatic presentation due to botulinum toxin treatment until the time they are fully symptomatic and are at least 3 months after the last injection\n9. Increased daytime sleepiness (Epworth Sleepiness Scale (ESS\\>10))\n10. Past or present history of any neurological disorders (except for LD and co-occurring voice tremor), such as stroke, movement disorders, brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases, alcoholism, drug dependence.\n11. Past or present history of any psychiatric problems, such as schizophrenia, major and\u002For bipolar depression, or obsessive-compulsive disorder\n12. Current use of medication(s) affecting the central nervous system\n13. Past or present history of brain and\u002For laryngeal surgery\n14. Presence of certain tattoos, ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve, etc.) that are not MRI comparable and\u002For cannot be removed for the purpose of MRI study participation","ALL","21 Years","80 Years",{"count":20,"type":21},8,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Using a comprehensive approach of clinico-behavioral testing and neuroimaging, the researchers will examine the clinical effects of the extended-release formulation of sodium oxybate on voice symptoms in spasmodic dysphonia in an open-label, proof-of-concept, dose-finding study.",[27,28,29],"Spasmodic Dysphonia","Laryngeal Dystonia","Voice Tremor","NOT_YET_RECRUITING","2026-04-25",{"date":33,"type":34},"2026-04-28","ACTUAL",{"date":36,"type":21},"2026-10-01",{"date":38,"type":21},"2027-09-30",{"name":40,"class":41},"Kristina Simonyan","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100627073","brain-network-changes-after-vibro-tactile-stimulation-in-laryngeal-dystonia-100627073","NCT07443891","Brain Network Changes After Vibro-tactile Stimulation in Laryngeal Dystonia","Functional Neural Network Changes After Vibro-tactile Stimulation in Laryngeal Dystonia","Neuro-VTS-LD","LD Inclusion Criteria:\n\n* Diagnosis of laryngeal dystonia previously made by a voice disorder specialist and confirmed by Dr. Misono, UM Otolaryngology.\n\nLD Exclusion Criteria:\n\n* Regular intake of benzodiazepines\n* Cognitive impairment: score \\\u003C 27 on Mini-mental state examination; score \\> 19 on Beck depression inventory\n* Identifies with a neurological or musculoskeletal impairment affecting speech motor function. These impairments may include a form of: Dyskinesia, Dystonia, Essential Tremor, Huntington's Disease, Multiple System Atrophy, Muscle Tension Dysphonia, Parkinsonism, Progressive Supranuclear Palsy, Spasticity, Intracranial Neoplasm (brain tumor), Spinal Neoplasm, Cerebrovascular Accident (Stroke), Mild Traumatic Brain Injury, Intracranial Hemorrhage, Multiple Sclerosis\n* Subjects with any type of bio-implant activated by mechanical, electronic, or magnetic means (e.g. cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.).\n* Subjects with any type of ferromagnetic bio-implant that could potentially be displaced or damaged, such as aneurysm clips, metallic skull plates, etc.\n* Pregnant females (if questionable doubt, self-test with over-the-counter pregnancy kit).\n* Subjects that exhibit noticeable anxiety and\u002For claustrophobia.\n* Subjects who have cardiac or known circulatory impairment, and\u002For the inability to perspire (poor thermoregulatory function).\n* Subjects who have known conditions which can lead to emergency medical care.\n* Subjects who have been diagnosed by a physician as having a psychiatric disorder, substance abuse, neurological, or cardiovascular disease, had a brain tumor or stroke, started taking chemotherapy or immunomodulatory agents, or had any radiation treatment that could affect the brain.\n* Subjects who have gotten a non-removable piercing or permanent eyeliner.\n* Subjects who have had a head injury that caused the loss of consciousness for more than 30 minutes or have amnesia for more than 24 hours.\n* Anyone with a history of head trauma that may have caused Traumatic Brain Injury (TBI), or some type of metal in the body, either from a medical procedure or an injury.\n* Any subject with a professional or academic link to one of the PIs.\n* We will not enroll vulnerable populations (i.e., fetuses, neonates, pregnant women, children under the age of 18 years, or prisoners).\n\nHealthy Controls Inclusion Criteria:\n\n* Healthy adults, aged 18-75 years with no known neurological or orthopedic deficits that may affect speech motor functions.\n\nHealthy Controls Exclusion Criteria:\n\n* No history of impairments affecting speech or voice function\n* Voice Handicap Index-10 (VHI-10) score above normative cut-off values\n* Regular intake of benzodiazepines.\n* Cognitive impairment: score \\\u003C 27 on Mini-mental state examination; score \\> 19 on Beck depression inventory.\n* Subjects with any type of bio-implant activated by mechanical, electronic, or magnetic means (e.g. cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.).\n* Subjects with any type of ferromagnetic bio-implant that could potentially be displaced or damaged, such as aneurysm clips, metallic skull plates, etc.\n* Pregnant females (if questionable doubt, self-test with over-the-counter pregnancy kit).\n* Subjects that exhibit noticeable anxiety and\u002For claustrophobia.\n* Subjects who have cardiac or known circulatory impairment, and\u002For the inability to perspire (poor thermoregulatory function).\n* Subjects who have known conditions which can lead to emergency medical care.\n* Subjects who have been diagnosed by a physician as having a psychiatric disorder, substance abuse, neurological, or cardiovascular disease, had a brain tumor or stroke, started taking chemotherapy or immunomodulatory agents, or had any radiation treatment that could affect the brain.\n* Subjects who have gotten a non-removable piercing or permanent eyeliner.\n* Subjects who have had a head injury that caused the loss of consciousness for more than 30 minutes or have amnesia for more than 24 hours.\n* Anyone with a history of head trauma that may have caused Traumatic Brain Injury (TBI), or some type of metal in the body, either from a medical procedure or an injury.\n* Any subject with a professional or academic link to one of the PIs.\n* We will not enroll vulnerable populations (i.e., fetuses, neonates, pregnant women, children under the age of 18 years, or prisoners).",true,"18 Years","75 Years",{"count":55,"type":21},20,[57],"NA","Laryngeal dystonia (LD) is a focal dystonia affecting laryngeal muscles, causing involuntary spasms that impair speech production. Recent research demonstrated that non-invasive vibrotactile stimulation (VTS) of the laryngeal area can provide acute symptom relief in up to 57% of patients, with improvements in voice quality and reductions in perceived speech effort lasting from minutes to several days. However, the neural mechanisms underlying this therapeutic effect and the factors determining individual treatment response remain incompletely understood. The objective is to evaluate the acute effects of VTS on voice and speech parameters in participants with LD while characterizing associated changes in brain resting-state networks using magnetic resonance imaging (MRI).",[28],"RECRUITING","2026-03-16",{"date":63,"type":34},"2026-03-19",{"date":65,"type":34},"2026-01-14",{"date":67,"type":21},"2027-02-28",{"name":69,"class":41},"University of Minnesota",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":42},"100446615","effects-of-neuromodulation-in-laryngeal-dystonia-100446615","NCT05095740","Effects of Neuromodulation in Laryngeal Dystonia","The Effects of Neuromodulation on Phonatory Function in Laryngeal Dystonia","Inclusion Criteria:\n\n* Age range is 21-85 years\n* Diagnosis of Laryngeal Dystonia (LD)\n* Subject is able to give informed consent\n* Symptoms at worst severity if receiving botulinum toxin injections\n* Subject has signed the consent form\n\nExclusion Criteria:\n\n* Other forms of dystonia\n* Vocal fold pathology or paralysis\n* Essential tremor\n* Laryngeal cancer or other neurologic conditions with medications affecting the central nervous system\n* History of laryngeal surgery\n* Adults lacking the ability to consent or complete the assessments and intervention\n* Seizure in the last 2 years\n* Contraindications to rTMS","85 Years",{"count":79,"type":21},25,[57],"Laryngeal dystonia (LD) causes excessive vocal fold abduction (opening) or adduction (closing) leading to decreased voice quality, job prospects, self-worth and quality of life. Individuals with LD often experience episodic breathy voice, decreased ability to sustain vocal fold vibration, frequent pitch breaks and in some cases, vocal tremor. While neuroimaging investigations have uncovered both cortical organization and regional connectivity differences in structures in parietal, primary somatosensory and premotor cortices of those with LD, there remains a lack of understanding regarding how the brains of those with LD function to produce phonation and how these might differ from those without LD. Intervention options for people with LD are limited to general voice therapy techniques and Botulinum Toxin (Botox) injections to the posterior cricoarytenoid (PCA) and\u002For TA (thyroarytenoid) often bilaterally, to alleviate muscle spasms in the vocal folds. However, the effects of injections are short-lived, uncomfortable, and variable. To address this gap, the aim of this study is to investigate the effectiveness of repetitive transcranial magnetic stimulation (rTMS), a non-invasive neuromodulation technique, in assessing cortical excitability and inhibition of laryngeal musculature. Previous work conducted by the investigator has demonstrated decreased intracortical inhibition in those with adductor laryngeal dystonia (AdLD) compared to healthy controls. The investigators anticipate similar findings in individuals with with other forms of LD, where decreased cortical inhibition will likely be noted in the laryngeal motor cortex. Further, following low frequency (inhibitory) rTMS to the laryngeal motor brain area, it is anticipated that there will be a decrease in overactivation of the TA muscle. To test this hypothesis, a proof-of-concept, randomized study to down-regulate cortical motor signal to laryngeal muscles will be compared to those receiving an equal dose of sham rTMS. Previous research conducted by the investigator found that a single session of the proposed therapy produced positive phonatory changes in individuals with AdLD and justifies exploration in LD.",[28,83],"Focal Dystonia",[85,86,87],"transcranial magnetic stimulation","randomized control trial","rTMS","2026-02-19",{"date":90,"type":34},"2026-02-20",{"date":92,"type":34},"2021-06-10",{"date":94,"type":21},"2026-12-31",{"name":96,"class":41},"MGH Institute of Health Professions",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":42},"100579890","tdcs-for-laryngeal-dystonia-100579890","NCT06830174","tDCS for Laryngeal Dystonia","Network Targeted Transcranial Direct Current Stimulation (tDCS) as a Treatment for Laryngeal Dystonia (LD)","Inclusion Criteria:\n\n* Participants must be clinically evaluated for the diagnosis of LD or have the proof of LD diagnosis. (Not applicable for control participants)\n* No other known or history of speech, voice disorder other than LD.\n* Provision of signed and dated informed consent form.\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Must not be pregnant.\n\nExclusion Criteria:\n\n* All individuals who do not meet the above mentioned criteria are excluded from the study.\n* Subjects with a history of epilepsy or depression or is claustrophobic.","65 Years",{"count":5,"type":21},[57],"This project will apply transcranial direct current stimulation (tDCS) to multiple brain areas to evaluate the effects as a potential treatment for laryngeal dystonia (formerly spasmodic dysphonia).",[28],"2026-02-06",{"date":111,"type":34},"2026-02-09",{"date":113,"type":34},"2025-04-14",{"date":115,"type":21},"2026-12",{"name":117,"class":41},"Yale University",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":51,"sex":16,"minAge":52,"maxAge":18,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":42},"100455915","early-phase-1-understanding-disorder-specific-neural-pathophysiology-in-laryngeal-dystonia-and-voice-tremor-100455915","NCT05216770","Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor","Inclusion criteria:\n\n1. Males and females of diverse racial and ethnic background;\n2. Age 18-80 years;\n3. Native English speakers;\n4. Right-handed;\n5. Normal cognitive status;\n6. Patients will have laryngeal dystonia or voice tremor;\n7. Healthy controls will be healthy individuals without neurological, psychiatric or otolaryngological problems.\n\nExclusion criteria:\n\n1. Subjects who are incapable of giving informed consent;\n2. Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding. All women of childbearing potential will have a urine pregnancy test performed before MRI, which must be negative for participation in the imaging studies;\n3. Subjects with a past or present medical history of (a) neurological problems, such as stroke, movement disorders (other than specified LD and VT in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases; (b) psychiatric problems, such as schizophrenia, bipolar depression, obsessive-compulsive disorder, alcoholism, drug dependence; (c) laryngeal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis;\n4. Patients with any other form of dystonia;\n5. Patients who have dystonia symptoms at rest or have a presence of mirror dystonia;\n6. Patients who are not symptomatic due to treatment with botulinum toxin injections into the affected muscles. The duration of positive effects of botulinum toxin varies from patient to patient but lasts, on average, for 3-4 months. All patients will be evaluated to ensure that they are fully symptomatic and are at least 3 months post-injection before participation;\n7. To avoid the confounding effect of centrally acting drugs, all study participants will be questioned about any prescribed or over-the-counter medications as part of their initial screening. Those patients who receive medication(s) affecting the central nervous system will be excluded;\n8. Patients will be asked whether they have undergone any head or neck surgery, which resulted in changes in regional anatomy or innervation. Because brain or laryngeal surgery may potentially lead to brain structure and function re-organization, all patients with such a history will be excluded;\n9. Subjects who have certain tattoos and ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve) that cannot be removed for MRI studies.",{"count":125,"type":21},165,[127],"EARLY_PHASE1","The researchers will examine functional neural correlates that differentiate between laryngeal dystonia and voice tremor and contribute to disorder-specific pathophysiology using a cross-disciplinary approach of multimodal brain imaging.",[28,27,130],"Tremor","2025-11-24",{"date":133,"type":34},"2025-12-02",{"date":135,"type":34},"2022-03-24",{"date":137,"type":21},"2027-08-31",{"name":139,"class":41},"Massachusetts Eye and Ear Infirmary",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":51,"sex":16,"minAge":52,"maxAge":18,"enrollmentInfo":146,"targetDuration":4,"studyType":147,"phases":4,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":154,"locationsCount":42},"100450792","characterization-of-clinical-phenotypes-of-laryngeal-dystonia-and-voice-tremor-100450792","NCT05150106","Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor","Inclusion criteria:\n\n1. Males and females of diverse racial and ethnic backgrounds;\n2. Age 18-80 years;\n3. Native English speakers;\n4. Right-handed;\n5. Normal cognitive status;\n6. Patients will have laryngeal dystonia or voice tremor;\n7. Healthy controls will be healthy individuals without neurological, psychiatric or otolaryngological problems.\n\nExclusion criteria:\n\n1. Subjects who are incapable of giving informed consent;\n2. Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding. All women of childbearing potential will have a urine pregnancy test performed before MRI, which must be negative for participation in the imaging studies;\n3. Subjects with a past or present medical history of (a) neurological problems, such as stroke, movement disorders (other than specified LD and VT in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases; (b) psychiatric problems, such as schizophrenia, bipolar depression, obsessive-compulsive disorder, alcoholism, drug dependence; (c) laryngeal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis;\n4. Patients with any other form of dystonia;\n5. Patients who have dystonia symptoms at rest or have a presence of mirror dystonia;\n6. Patients who are not symptomatic due to treatment with botulinum toxin injections into the affected muscles. The duration of positive effects of botulinum toxin varies from patient to patient but lasts, on average, for 3-4 months. All patients will be evaluated to ensure that they are fully symptomatic and are at least 3 months post-injection before participation;\n7. To avoid the confounding effect of centrally acting drugs, all study participants will be questioned about any prescribed or over-the-counter medications as part of their initial screening. Those patients who receive medication(s) affecting the central nervous system will be excluded;\n8. Patients will be asked whether they have undergone any head or neck surgery, which resulted in changes in regional anatomy or innervation. Because brain or laryngeal surgery may potentially lead to brain structure and function re-organization, all patients with such a history will be excluded;\n9. Subjects who have certain tattoos and ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve) that cannot be removed for MRI studies.",{"count":125,"type":21},"OBSERVATIONAL","The researchers will systematically evaluate current and novel clinical voice assessment tools and measures to elucidate distinct clinical phenotypes of those with laryngeal dystonia and voice tremor.",[28,27,130],{"date":133,"type":34},{"date":152,"type":34},"2022-11-07",{"date":137,"type":21},{"name":139,"class":41},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":18,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":171,"locationsCount":42},"100450791","deep-brain-stimulation-in-laryngeal-dystonia-and-voice-tremor-100450791","NCT05150093","Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor","Inclusion\n\n1. Clinical indications to proceed with DBS implantation, as determined by the clinical multidisciplinary movement disorders board, including: a) definitive diagnosis of essential tremor or dystonia, b) medically refractory disease, c) adequate performance on neuropsychological evaluation as determined by a licensed clinical neuropsychologist.\n2. The ability to comply with test directions, complete pre-operative task training, and provide informed consent.\n3. Age 18-80 years.\n\nExclusion\n\n1\\. Inability to understand or perform the task outlined in the protocol during a pre-surgery training session. 2. Significant hearing loss.\n\n3\\. Cortical venous anatomy that could potentially obstruct ECoG electrode placement, as determined by the surgeon, visualized on pre-op MRI or during surgery.",{"count":162,"type":21},120,[57],"The goals of this project are 1) to determine the incidence of neurological voice disorders in patients with dystonia and essential tremor undergoing deep brain stimulation (DBS), 2) investigate the neuroimaging and intracranial neurophysiology correlates of voice dysfunction in these subjects, and subsequently 3) determine the effects of DBS on voice function.",[28,27,130,166],"Dystonia",{"date":133,"type":34},{"date":169,"type":34},"2022-06-21",{"date":137,"type":21},{"name":139,"class":41},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":51,"sex":16,"minAge":52,"maxAge":18,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":188,"locationsCount":42},"100394845","brain-computer-interfaces-in-laryngeal-dystonia-100394845","NCT04421365","Brain-Computer Interfaces in Laryngeal Dystonia","Adaptive Closed-loop Brain-computer Interface Therapeutic Intervention in Laryngeal Dystonia","Inclusion criteria:\n\n1. Patients will have clinically documented isolated adductor laryngeal dystonia (ADLD) without any other forms of dystonia or tremor. ADLD causes involuntary spasms during vocal fold adduction, leading to voice breaks predominantly on vowels and strained, strangles quality of voice, predominantly affecting voice production during the speaking. Only patients with the ADLD form of disorder will be recruited to minimize the impact of heterogeneity of voice symptomatology on the outcome of these phase 1 studies;\n2. Healthy controls will be healthy individuals with a negative history of any neurological, psychiatric, or laryngeal problems;\n3. Age from 18 to 80 years;\n4. Native English speakers. Non-English-speaking subjects will not be recruited because brain activation and neural network organization are different between native and non-native English speakers;\n5. Right-handedness (based on Edinburgh Handedness Inventory). Left-handed subjects will not be recruited because brain activation and neural network organization are different between right and left-handed individuals;\n6. Normal cognitive status (based on Montreal Cognitive Assessment).\n\nExclusion criteria:\n\n1. Subjects who are incapable of giving informed consent will be excluded from the study;\n2. Pregnant or breastfeeding women until the time they are no longer pregnant or breastfeeding will be excluded from the study. All women of childbearing potential will undergo a urine pregnancy test, which must be negative for study participation;\n3. Subjects with a past or present medical history of (a) neurological problems, such as stroke, movement disorders (except for ADLD in the patient group), brain tumors, ataxias, myopathies, myasthenia gravis, demyelinating diseases; (b) psychiatric problems, such as schizophrenia, bipolar depression, obsessive-compulsive disorder; (c) laryn¬geal problems, such as vocal fold paralysis, paresis, carcinoma;\n4. Subjects with impaired hearing, vision, and speaking abilities (except for ADLD), as these would most typically have a neurological origin;\n5. Patients who have dystonia symptoms at rest in order to avoid the potential confound of dystonic spasms occurring during the asymptomatic task production;\n6. Patients who are not symptomatic due to the treatment with botulinum toxin injections into the affected muscles. The duration of positive effects of botulinum toxin varies from patient to patient but lasts on average for 3-4 months. All patients will be evaluated to ensure that they are fully symptomatic and are at least three months post-injection prior to study participation;\n7. To avoid the possibility of confounding effects of drugs acting upon the central nervous system, all subjects will be questioned about any prescribed or over-the-counter medications as part of their initial screening. Those who are on medication(s) affecting the central nervous system will be excluded;\n8. Subjects with implanted deep brain stimulators will be excluded from the study;\n9. Subjects will be asked whether they have undergone any head and neck surgeries, particularly any brain surgery and laryngeal surgeries, such as thyroplasty, laryngeal denervation, and selective laryngeal adductor denervation-reinnervation. Because both brain and laryngeal surgery may potentially lead to the brain structure and function re-organization, all subjects with a history of brain and\u002For laryngeal surgery will be excluded from the study.",{"count":180,"type":21},40,[57],"The researchers will develop and evaluate the use of adaptive closed-loop brain-computer interface therapeutic intervention in laryngeal dystonia.",[28],{"date":133,"type":34},{"date":186,"type":34},"2022-04-18",{"date":137,"type":21},{"name":40,"class":41},{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":147,"phases":4,"briefSummary":197,"conditions":198,"keywords":201,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":42},"100289071","imaging-genetics-of-laryngeal-dystonia-100289071","NCT03042975","Imaging Genetics of Laryngeal Dystonia","Inclusion criteria:\n\n1. Males and females of diverse racial and ethnic background, with age across the lifespan;\n2. Laryngeal Dystonia patients\n\n   * phenotype: adductor or abductor\n   * genotype: familial or sporadic\n3. Voice Tremor patients\n\n   * essential or\n   * dystonic\n4. Muscle tension dysphonia patients\n5. Unaffected relatives of laryngeal dystonia patients with\n\n   * familial laryngeal dystonia\n   * early-onset laryngeal dystonia (onset at ≤ 35 y.o.)\n   * typical onset laryngeal dystonia (onset at ≥ 40 y.o.)\n6. Native English speakers.\n7. Right-handedness.\n8. Normal cognitive status.\n\nExclusion criteria:\n\n1. Subjects who are incapable of giving informed consent.\n2. Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding.\n3. Subjects with past or present medical history of (a) major neurological problems, such as stroke, movement disorders (other than LD and VT in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases, alcoholism, drug dependence; (b) psychiatric problems, such as schizophrenia, bipolar depression, obsessive-compulsive disorder; (c) laryn¬geal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis.\n4. Patients who are not symptomatic due to treatment with botulinum toxin injections into the laryngeal muscles.\n5. Subjects who receive medication(s) affecting the central nervous system.\n6. Subjects with a history of major brain and\u002For laryngeal surgery.\n7. Subjects who have tattoos, ferromagnetic objects in their bodies that cannot be removed for imaging study participation.",{"count":196,"type":21},410,"The contribution of genetic risk factors to the development of focal dystonias is evident. However, understanding of how variations in the causative gene expression lead to variations in brain abnormalities in different phenotypes of dystonia (e.g., familial, sporadic) remains limited. The research program of the investigators is set to determine the relationship between brain changes and genetic risk factors in laryngeal dystonia (or spasmodic dysphonia). The researchers use a novel approach of combined imaging genetics, next-generation DNA sequencing, and clinical-behavioral testing. The use of a cross-disciplinary approach as a tool for the discovery of the mediating neural mechanisms that bridge the gap from DNA sequence to the pathophysiology of dystonia holds a promise for the understanding of the mechanistic aspects of brain function affected by risk gene variants, which can be used reliably for the discovery of associated genes and neural integrity markers for this disorder. The expected outcome of this study may lead to better clinical management of this disorder, including its improved detection, accurate diagnosis, and assessment of the risk of developing dystonia in family members.",[28,199,29,200],"Unaffected Relatives of Laryngeal Dystonia Patients","Muscle Tension Dysphonia",[202,203,204,205],"dystonia","spasmodic dysphonia","imaging","genetics",{"date":133,"type":34},{"date":208,"type":34},"2017-01-23",{"date":210,"type":21},"2028-07-31",{"name":40,"class":41},{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":147,"phases":4,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":42},"100478139","deep-brain-stimulation-for-laryngeal-dystonia-from-mechanism-to-optimal-application-100478139","NCT05506085","Deep Brain Stimulation for Laryngeal Dystonia: From Mechanism to Optimal Application","Inclusion Criteria:\n\n* Patients with ADLD and ADLD plus tremor, as diagnosed by routine clinical examination by laryngologist, speech language pathologist, and neurologist.\n* Patients undergoing globus pallidus interna (GPi) deep brain stimulation (DBS) for ADLD with tremor\n* Age range of 18-80 years\n* Native speakers of American English will be recruited since there are known differences in voice and neural signals of native and non-native speakers\n* No evidence for dementia as assessed by neurologist.\n* No evidence for severe untreated mood disorder as assessed by neurologist, or as evident on self-report (Beck Depression Inventory-II score \\> 29, Beck Anxiety Inventory Score \\> 26.\n* At least 3 months since last botulinum toxin injection and the patients would need to be fully symptomatic with no residual effects of botulinum toxin on voice quality.\n\nExclusion Criteria:\n\n* Individuals younger than 18 years and older than 80 years of age.\n* Women who plan to become pregnant during the study period or are currently breastfeeding.\n* Prior history of stroke, brain surgery, or other neurological disorder besides the one under study.\n* Prior laryngeal framework surgeries or other disorders affecting the vocal folds\n* Patients who are asymptomatic due to treatment with botulinum toxin into the vocal folds.\n* Presence of ferromagnetic implants and cardiac implants that would be contraindicated to MRI\n* Gagging or discomfort that would preclude the placement of the endoscope to visualize the larynx\n* Dementia, severe depression or severe anxiety.\n* Any clinical condition or medication judged by the investigators to potentially preclude the patient from safely completing awake brain surgery and research protocols.","70 Years",{"count":220,"type":21},12,"Deep Brain Stimulation (DBS) is a neurosurgical procedure used to treat tremors, and dystonia. This study will enroll people who have a form of focal dystonia that affects their vocal cords called Adductor Laryngeal dystonia (ADLD). Participants will undergo Deep Brain Stimulation surgery to treat laryngeal dystonia as part of their clinical care. Before surgery, as part of the study they will have specialized testing to study the movement of the vocal cords, as well as functional magnetic resonance imaging (fMRI). While in the operating room, researchers will examine brain waves to better understand how faulty brain firing patterns lead to dystonia. After surgery, and activation of the deep brain stimulator, participants will repeat speech testing and vocal cord imaging as well as magnetic resonance imaging (MRI).",[28,223],"Adductor Spastic Dysphonia of Dystonia",[225],"deep brain stimulation","2025-07-15",{"date":228,"type":34},"2025-07-17",{"date":230,"type":34},"2022-10-01",{"date":232,"type":21},"2030-08-01",{"name":234,"class":41},"Indiana University"]